312 related articles for article (PubMed ID: 28240870)
1. Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy.
Xu X; Wu J; Liu Y; Saw PE; Tao W; Yu M; Zope H; Si M; Victorious A; Rasmussen J; Ayyash D; Farokhzad OC; Shi J
ACS Nano; 2017 Mar; 11(3):2618-2627. PubMed ID: 28240870
[TBL] [Abstract][Full Text] [Related]
2. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M
J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023
[TBL] [Abstract][Full Text] [Related]
3. Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy.
Xu X; Saw PE; Tao W; Li Y; Ji X; Yu M; Mahmoudi M; Rasmussen J; Ayyash D; Zhou Y; Farokhzad OC; Shi J
Nano Lett; 2017 Jul; 17(7):4427-4435. PubMed ID: 28636389
[TBL] [Abstract][Full Text] [Related]
4. Ultra-pH-Responsive and Tumor-Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Anti-Cancer Efficacy.
Xu X; Wu J; Liu Y; Yu M; Zhao L; Zhu X; Bhasin S; Li Q; Ha E; Shi J; Farokhzad OC
Angew Chem Int Ed Engl; 2016 Jun; 55(25):7091-7094. PubMed ID: 27140428
[TBL] [Abstract][Full Text] [Related]
5. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer.
Xiang B; Dong DW; Shi NQ; Gao W; Yang ZZ; Cui Y; Cao DY; Qi XR
Biomaterials; 2013 Sep; 34(28):6976-91. PubMed ID: 23777916
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Preliminary Biological Assessment of Carborane-Loaded Theranostic Nanoparticles to Target Prostate-Specific Membrane Antigen.
Meher N; Seo K; Wang S; Bidkar AP; Fogarty M; Dhrona S; Huang X; Tang R; Blaha C; Evans MJ; Raleigh DR; Jun YW; VanBrocklin HF; Desai TA; Wilson DM; Ozawa T; Flavell RR
ACS Appl Mater Interfaces; 2021 Nov; 13(46):54739-54752. PubMed ID: 34752058
[TBL] [Abstract][Full Text] [Related]
7. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of KUE-siRNA Conjugates for Prostate Cancer Cell-Targeted Gene Silencing.
Yang C; Ma D; Lu L; Yang X; Xi Z
Chembiochem; 2021 Oct; 22(19):2888-2895. PubMed ID: 34263529
[TBL] [Abstract][Full Text] [Related]
9. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
[TBL] [Abstract][Full Text] [Related]
10. Pre- and Post-Transcriptional Regulation of cFLIP for Effective Cancer Therapy Using pH-Ultrasensitive Nanoparticles.
Phung CD; Tran TH; Choi JY; Jeong JH; Ku SK; Yong CS; Kim JO
ACS Appl Mater Interfaces; 2021 Feb; 13(5):5999-6010. PubMed ID: 33506682
[TBL] [Abstract][Full Text] [Related]
11. Efficacious delivery of protein drugs to prostate cancer cells by PSMA-targeted pH-responsive chimaeric polymersomes.
Li X; Yang W; Zou Y; Meng F; Deng C; Zhong Z
J Control Release; 2015 Dec; 220(Pt B):704-14. PubMed ID: 26348387
[TBL] [Abstract][Full Text] [Related]
12. Intracellular cleavable poly(2-dimethylaminoethyl methacrylate) functionalized mesoporous silica nanoparticles for efficient siRNA delivery in vitro and in vivo.
Lin D; Cheng Q; Jiang Q; Huang Y; Yang Z; Han S; Zhao Y; Guo S; Liang Z; Dong A
Nanoscale; 2013 May; 5(10):4291-301. PubMed ID: 23552843
[TBL] [Abstract][Full Text] [Related]
13. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
[TBL] [Abstract][Full Text] [Related]
14. A Novel Prostate-Specific Membrane-Antigen (PSMA) Targeted Micelle-Encapsulating Wogonin Inhibits Prostate Cancer Cell Proliferation via Inducing Intrinsic Apoptotic Pathway.
Zhang H; Liu X; Wu F; Qin F; Feng P; Xu T; Li X; Yang L
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27196894
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth.
Liu XQ; Xiong MH; Shu XT; Tang RZ; Wang J
Mol Pharm; 2012 Oct; 9(10):2863-74. PubMed ID: 22924580
[TBL] [Abstract][Full Text] [Related]
16. Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo.
Wu X; Tai Z; Zhu Q; Fan W; Ding B; Zhang W; Zhang L; Yao C; Wang X; Ding X; Li Q; Li X; Liu G; Liu J; Gao S
Int J Nanomedicine; 2014; 9():5431-40. PubMed ID: 25473281
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a PSMA-targeted BNF nanoparticle construct.
Behnam Azad B; Banerjee SR; Pullambhatla M; Lacerda S; Foss CA; Wang Y; Ivkov R; Pomper MG
Nanoscale; 2015 Mar; 7(10):4432-42. PubMed ID: 25675333
[TBL] [Abstract][Full Text] [Related]
18. Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer.
Liu Y; Gunda V; Zhu X; Xu X; Wu J; Askhatova D; Farokhzad OC; Parangi S; Shi J
Proc Natl Acad Sci U S A; 2016 Jul; 113(28):7750-5. PubMed ID: 27342857
[TBL] [Abstract][Full Text] [Related]
19. A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy.
Wang Y; Zhang Y; Ru Z; Song W; Chen L; Ma H; Sun L
J Nanobiotechnology; 2019 Aug; 17(1):91. PubMed ID: 31451114
[TBL] [Abstract][Full Text] [Related]
20. Targeted systemic delivery of a therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice.
Wang XL; Xu R; Wu X; Gillespie D; Jensen R; Lu ZR
Mol Pharm; 2009; 6(3):738-46. PubMed ID: 19296675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
